Syndax to Host R&D Day Highlighting its Late-Stage Programs and Early-Stage Assets on July 14, 2026

Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will host an R&D Day on Tuesday, July 14, 2026, at ...
Enid News & Eagle

Eikon Therapeutics Presents Data on Clinical-Stage Programs at the 2026 Annual Meeting of the ...

TeLuRide-005, a Phase 2 trial of EIK1001 in first-line patients with stage 4 NSCLC completed enrollment of both non-squamous and squamous cohorts and reports updated rates of response and disease ...
Business Wire

Precision BioSciences Sets Strategic Priorities for 2026 Focused on Continued Advancement of Clinical-Stage Programs PBGENE-HBV for Chronic Hepatitis B and PBGENE-DMD for ...

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing ...
Seeking Alpha

Biontech outlines €2B–€2.3B revenue target for 2026 while advancing late-stage oncology pipeline and leadership transition

CEO Ugur Sahin highlighted that BioNTech maintained its leadership in the COVID vaccine market, launching a variant-adapted vaccine in partnership with Pfizer, now distributed in over 180 countries ...

Eikon Therapeutics Presents Data on Clinical-Stage Programs at the 2026 Annual Meeting of the American Society of Clinical Oncology

TeLuRide-005, a Phase 2 trial of EIK1001 in first-line patients with stage 4 NSCLC completed enrollment of both non-squamous and squamous cohorts and reports updated rates of response and disease ...